Drug Profile
Research programme: GPCR modulators - cancer therapies - Sosei Heptares
Alternative Names: Adenosine A2A modulators; CXCR-4 modulatorsLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Heptares Therapeutics
- Developer AstraZeneca; Sosei Heptares
- Class Small molecules
- Mechanism of Action Adenosine A2A receptor antagonists; Chemokine receptor antagonists; G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
- 03 Dec 2018 Heptares Therapeutics has merged with Sosei to form Sosei Heptares